Table 4. Univariate and multivariate analyses of various factors for PFS and OS.

	No. of patients	PFS				OS
		Univariate analysis		Multivariate analysis		Univariate analysis		Multivariate analysis
		HR (95% CI)	P	HR (95% CI)	P	HR (95% CI)	P	HR (95% CI)	P
Age, years (continuous)	158	1.016 (0.994-1.039)	0.154			1.043 (1.013-1.075)	0.005	1.044 (1.014-1.075)	0.004
Histology
Non-serous	28	1 (Reference)				1 (Reference)
Serous	124	1.226 (0.611-2.462)	0.567			1.072 (0.454-2.530)	0.874
Tumor grade
Grade 1	7	1 (Reference)				1 (Reference)
Grade 2-3	151	1.364 (0.576-3.186)	0.227			1.140 (0.345-3.765)	0.83
Preoperative CA 125, U/ml
≤500	58	1 (Reference)		1 (Reference)		1 (Reference)
>500	94	1.722 (1.030-2.881)	0.038	1.713 (1.053-2.789)	0.033	1.540 (0.782-3.033)	0.212
Suspected LN metastasis on preoperative imaging studies
No	69	1 (Reference)				1 (Reference)
Yes	83	1.326 (0.809-2.171)	0.263			1.461 (0.746-2.860)	0.269
LN metastasis
No	55	1 (Reference)		1 (Reference)		1 (Reference)
Yes	103	2.060 (1.162-3.651)	0.013	2.238 (1.304-3.841)	0.004	1.331 (0.628-2.820)	0.455
Residual disease
NGR	39	1 (Reference)				1 (Reference)
R < 1 cm	113	1.102 (0.604-2.011)	0.752			1.251 (0.498-3.142)	0.634
Lymphadenectomy
LNS	58	1 (Reference)		1 (Reference)		1 (Reference)		1 (Reference)
LND	94	0.613 (0.384-0.979)	0.041	0.629 (0.400-0.989)	0.048	0.310 (0.163-0.588)	<0.001	0.250 (0.137-0.456)	<0.001

PFS, progression-free survival; OS, overall survival; HR, hazard ratio; CI, confidence interval; CA 125, cancer antigen 125; NGR, no gross residual disease; R, residual disease; LNS, lymph node sampling; LND, lymph node dissection